Join OS Therapies for a Deep Dive into Cancer Treatments
OS Therapies (NYSE American: OSTX), an emerging clinical-stage immunotherapy and biopharmaceutical company, is thrilled to extend an invitation to investors for an insightful webinar scheduled for October 30 at 4:15 p.m. ET. This exclusive event is an excellent opportunity to gain valuable insights into the company's groundbreaking pipeline and understand its impact on cancer therapy.
Insights from the Leadership Team
Hosted by RedChip Companies, this engaging session will feature the perspectives of OS Therapies’ Chairman and CEO Paul Romness, along with Chief Business Officer Gerald Commissiong. Both will provide in-depth overviews of the company's innovative treatments targeting Osteosarcoma (OS) and other solid tumors. Their discussion will highlight the promising candidates, OST-HER2 and OST-tADC, designed to fill substantial gaps in pediatric cancer care and extend benefits to a wider array of solid tumors.
Transforming Pediatric Cancer Care
OS Therapies is on the verge of significant clinical advancements which can revolutionize the treatment landscape for pediatric and young adult patients suffering from cancer. The company's development programs have the potential to significantly alter the trajectory of cancer treatments that have historically lacked effective options.
Revenue Potential Through Diverse Streams
Potential revenue streams for OS Therapies underscore its financial strategy aimed at fostering growth. Out-licensing agreements for canines with osteosarcoma could yield upwards of $15 million. In addition, the human OS segment shows promise, potentially generating over $100 million. The innovative OST-tADC SiLinkers™ provide an additional $20-80 million in revenue opportunities. A valuable priority review voucher, estimated between $100-110 million, adds substantial prospects for the company’s future.
Interactive Q&A Session
A live question and answer segment with Mr. Romness and Mr. Commissiong will follow their presentation. This will allow attendees to engage directly, ask questions, and clarify their understanding of the company’s aspirations and technologies.
How to Register
Investors eager to attend this enlightening session can register for the free webinar. For more information, simply visit the registration link provided.
About OS Therapies
OS Therapies specializes in developing and commercializing proprietary treatments for Osteosarcoma and various solid tumors. The company’s flagship asset, OST-HER2, utilizes the immune-stimulatory properties of Listeria bacteria to elicit robust immune responses against the HER2 protein. OS Therapies has already completed enrollment for a Phase 2b clinical trial encompassing 41 patients with resected, recurrent osteosarcoma, with results anticipated in an upcoming quarter. Furthermore, OST-HER2 has received conditional approval for treating canine osteosarcoma by the U.S. Department of Agriculture.
Additionally, OS Therapies is developing a next-generation Antibody Drug Conjugate (ADC) platform known as tunable ADC (tADC), promising even greater efficacy through tailored antibody-linker-payload candidates, creating new treatment avenues.
Frequently Asked Questions
1. What is the purpose of the OS Therapies webinar?
The webinar aims to provide investors with insights into OS Therapies' innovative cancer treatments and future growth potential.
2. Who will be speaking at the event?
Chairman and CEO Paul Romness and Chief Business Officer Gerald Commissiong will lead the discussion.
3. How can I register for the webinar?
Investors can register for the free webinar via the registration link provided in the announcement.
4. What topics will be discussed during the Q&A session?
The Q&A session will cover company strategy, treatment developments, and any questions from participants related to cancer therapies.
5. How does OS Therapies support children with cancer?
OS Therapies is focused on developing novel treatments specifically aimed at filling the gaps in pediatric cancer care, improving outcomes for young patients.
